ALLcrimesfood&drugstaxestelecomcommercehealthconservationtransportationagricultureveteransbrowse all titles »
0

42 U.S.C. § 244bActivities relating to cardiomyopathy

submitted 82 years ago by Pub. L. 118-176 to r/title-42-THE-PUBLIC-HEALTH-AND-WELFARE · 384 words · no verdicts yet

in plain englishAI-generated · not legal advice

Within 18 months, the Secretary must report to Congress on CDC's cardiomyopathy research, covering both children and adults, while protecting privacy. The Secretary must also create a public risk assessment tool for cardiomyopathy, built with input from patient groups, medical societies, and other agencies.

(a) Report on CDC national cardiomyopathy activities. Within 18 months after December 23, 2024, the Secretary — acting through the CDC Director — must send Congress a report on what CDC's existing work has found about how common cardiomyopathy is and how it plays out across a person's life, from birth to adulthood. The report should focus especially on the natural course of the disease in both children and adults, and on estimates of how many emergency department visits and hospitalizations cardiomyopathy causes, again for both children and adults. This report must be made available to the public, but the Secretary must make sure the report follows all applicable federal and state privacy laws. (b) Improving risk assessments for individuals with cardiomyopathy. The Secretary must create and publish a cardiomyopathy risk assessment tool for both health care providers and individuals. At minimum, it must include: background information on how common cardiomyopathy is, how it affects health, and how it differs across all its forms in children, teens, and adults; a worksheet listing variables and conditions to help someone judge whether they are at risk; a separate worksheet listing variables and stages to help judge how far the disease has progressed in someone who has it; and guidelines on when people at risk, or with a family history of cardiomyopathy, should get screened. In building this tool, the CDC Director must ask for input from outside experts, including national patient advocacy groups that specialize in all forms of cardiomyopathy, medical professional societies that treat adults and children with the disease, and other relevant federal agencies. (c) Definition. In this section, "cardiomyopathy" means the same thing it means in section 244a.
the actual law source: uscode.house.gov ↗public domain
(a) Report on CDC national cardiomyopathy activities
(1) In general

Not later than 18 months after December 23, 2024, the Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall submit to Congress a report on findings generated from existing activities conducted by the Centers for Disease Control and Prevention to improve the understanding of the prevalence and epidemiology of cardiomyopathy across the lifespan, from birth to adulthood, with particular interest in the following:

(A)

The natural history of individuals with cardiomyopathy, in both the pediatric and adult population.

(B)

Estimates of cardiomyopathy-related emergency department visits and hospitalizations, in both the pediatric and adult population.

(2) Public access

Subject to paragraph (3), the report submitted under this subsection shall be made available to the public.

(3) Privacy protections

The Secretary shall ensure that this subsection is carried out in a manner that complies with all applicable privacy laws under Federal and State law.

(b) Improving risk assessments for individuals with cardiomyopathy
(1) In general

The Secretary shall develop and make publicly available a cardiomyopathy risk assessment for health care providers and individuals. Such risk assessment shall, at a minimum, include the following:

(A)

Background information on the prevalence, incidence, and health impact of cardiomyopathy, including all forms of cardiomyopathy and their effects on pediatric, adolescent, and adult individuals.

(B)

A worksheet with variables and conditions for an individual or health care provider to use in assessing whether an individual is at risk for cardiomyopathy.

(C)

A worksheet with variables and stages of progression for an individual or health care provider to use in assessing whether and to what extent cardiomyopathy has progressed in an individual.

(D)

Guidelines on cardiomyopathy screenings for individuals who are at risk for, or have a family history of, cardiomyopathy.

(2) Stakeholder input

In carrying out paragraph (1), the Director of the Centers for Disease Control and Prevention shall seek input from external stakeholders including—

(A)

representatives from national patient advocacy organizations expert in all forms of cardiomyopathy;

(B)

representatives from medical professional societies that specialize in the care of adults and pediatrics with cardiomyopathy; and

(C)

representatives from other relevant Federal agencies.

(c) Definition

In this section, the term “cardiomyopathy” has the meaning given to such term in section 244a of this title.

Source credit: (July 1, 1944, ch. 373, title III, § 312B, as added Pub. L. 118–176, § 2(a), Dec. 23, 2024, 138 Stat. 2607.)

history & why it existsrecord from the source credit
  • 1944Enacted · Pub. L. 118-176 · 138 Stat. 2607

A history note hasn’t been published yet. The record shows enactment by Pub. L. 118-176 on 1944-07-01.

all 0 arguments · sorted by: best

0/280

no arguments yet — make the first case